JAK1 and melanoma: Commensurate with activated JAK1/2 in ICB-resistant IFNγR1KO melanoma, Ruxo selectively suppressed IFNγR1KO but not scrambled control melanomas, highlighting Ruxo as a “targeted” therapy for ICB resistance.